Skip to main content
Erschienen in: Cancer Chemotherapy and Pharmacology 4/2013

01.04.2013 | Original Article

Correlation between expressions of ERCC1/TS mRNA and effects of gastric cancer to chemotherapy in the short term

verfasst von: Liqi Chen, Guoli Li, Jieshou Li, Chaogang Fan, Jian Xu, Bo Wu, Kun Liu, Caihua Zhang

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 4/2013

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To study the correlation between expression levels of ERCC1/TS mRNA and the susceptibility of preoperative chemotherapy for patients with gastric cancer.

Methods

A total of forty cases with advanced gastric cancer of T3–4N1–2M0 were treated with preoperative chemotherapy according to FLEEOX regimen based on endarterial-intravenous coadministration. Sufficient, fresh gastric tissue specimens were obtained with the help of gastroscope, and the expression levels of ERCC1/TS mRNA were detected by qRT-PCR before chemotherapy. The chemotherapeutic response was evaluated with Choi Criteria after chemotherapy, and pathologic remission extent was observed after surgery. The correlation between the expression levels of ERCC1/TS mRNA before chemotherapy and the chemotherapeutic effect based on imageology and pathology was analyzed.

Results

The response rate of Chemotherapy in this cohort was 80.0 % based on imageology and 51.43 % based on pathology. The expression levels of ERCC1/TS mRNA were significantly associated with imageology remission extent (P = 0.033, P = 0.025) and pathologic remission extent (P = 0.044, P = 0.016), respectively. The chemotherapeutic effect on patients with low-expression levels of ERCC1/TS mRNA was better.

Conclusions

From the perspective of pathology and imageology evaluating the preoperative chemotherapeutic response for patients with gastric cancer, ERCC1 and TS were used as the molecular predictors and provided prognostic information in this study.
Literatur
1.
Zurück zum Zitat Yang L (2006) Incidence and mortality of gastric cancer in China. World J Gastroenterol 12(1):17–20PubMed Yang L (2006) Incidence and mortality of gastric cancer in China. World J Gastroenterol 12(1):17–20PubMed
3.
Zurück zum Zitat Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ, Smith DB, Langley RE, Verma M, Weeden S, Chua YJ, Participants MT (2006) Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355(1):11–20. doi:10.1056/NEJMoa055531 PubMedCrossRef Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ, Smith DB, Langley RE, Verma M, Weeden S, Chua YJ, Participants MT (2006) Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355(1):11–20. doi:10.​1056/​NEJMoa055531 PubMedCrossRef
4.
Zurück zum Zitat Li G-L, Bao Y, Jiang J, Fan C-G, Wang Z-M, Li N, Li J-S (2008) Arteriovenous neoadjuvant FLEOX chemotherapy with nutritional support improves the resectable rate for advanced gastric cancer. Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery (5) Li G-L, Bao Y, Jiang J, Fan C-G, Wang Z-M, Li N, Li J-S (2008) Arteriovenous neoadjuvant FLEOX chemotherapy with nutritional support improves the resectable rate for advanced gastric cancer. Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery (5)
5.
Zurück zum Zitat Li GL, Fan CG, Bao Y, Jiang J, Li N, Li JS (2009) Neoadjuvant chemotherapy of FLEEOX regimen for unresectable gastric cancer resulting from advanced abdominal lymph nodes metastases. Zhonghua Wai Ke Za Zhi 47(15):1171–1174PubMed Li GL, Fan CG, Bao Y, Jiang J, Li N, Li JS (2009) Neoadjuvant chemotherapy of FLEEOX regimen for unresectable gastric cancer resulting from advanced abdominal lymph nodes metastases. Zhonghua Wai Ke Za Zhi 47(15):1171–1174PubMed
6.
Zurück zum Zitat Hwang SW, Lee DH, Lee SH, Park YS, Hwang JH, Kim JW, Jung SH, Kim NY, Kim YH, Lee KH, Kim HH, J Park do, HS Lee, HC Jung, IS Song (2010) Preoperative staging of gastric cancer by endoscopic ultrasonography and multidetector-row computed tomography. J Gastroenterol Hepatol 25(3):512–518. doi:10.1111/j.1440-1746.2009.06106.x PubMedCrossRef Hwang SW, Lee DH, Lee SH, Park YS, Hwang JH, Kim JW, Jung SH, Kim NY, Kim YH, Lee KH, Kim HH, J Park do, HS Lee, HC Jung, IS Song (2010) Preoperative staging of gastric cancer by endoscopic ultrasonography and multidetector-row computed tomography. J Gastroenterol Hepatol 25(3):512–518. doi:10.​1111/​j.​1440-1746.​2009.​06106.​x PubMedCrossRef
7.
Zurück zum Zitat Association JGC (2010) Japanese classification of gastric carcinoma, 14th ed (in Japanese). Kanehara & Co, Ltd., Tokyo Association JGC (2010) Japanese classification of gastric carcinoma, 14th ed (in Japanese). Kanehara & Co, Ltd., Tokyo
8.
Zurück zum Zitat Liu K, Li G, Fan C, Zhou C, Li J (2012) Adapted choi response criteria for prediction of clinical outcome in locally advanced gastric cancer patients following preoperative chemotherapy. Acta Radiol 53(2):127–134. doi:10.1258/ar.2011.110273 PubMedCrossRef Liu K, Li G, Fan C, Zhou C, Li J (2012) Adapted choi response criteria for prediction of clinical outcome in locally advanced gastric cancer patients following preoperative chemotherapy. Acta Radiol 53(2):127–134. doi:10.​1258/​ar.​2011.​110273 PubMedCrossRef
10.
Zurück zum Zitat Hofler H, Langer R, Ott K, Keller G (2007) Prediction of response to neoadjuvant chemotherapy in carcinomas of the upper gastrointestinal tract. Recent Results Cancer Res 176:33–36PubMedCrossRef Hofler H, Langer R, Ott K, Keller G (2007) Prediction of response to neoadjuvant chemotherapy in carcinomas of the upper gastrointestinal tract. Recent Results Cancer Res 176:33–36PubMedCrossRef
11.
Zurück zum Zitat Metzger R, Leichman CG, Danenberg KD, Danenberg PV, Lenz HJ, Hayashi K, Groshen S, Salonga D, Cohen H, Laine L, Crookes P, Silberman H, Baranda J, Konda B, Leichman L (1998) ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J Clin Oncol 16(1):309–316PubMed Metzger R, Leichman CG, Danenberg KD, Danenberg PV, Lenz HJ, Hayashi K, Groshen S, Salonga D, Cohen H, Laine L, Crookes P, Silberman H, Baranda J, Konda B, Leichman L (1998) ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J Clin Oncol 16(1):309–316PubMed
12.
Zurück zum Zitat Wei J, Zou Z, Qian X, Ding Y, Xie L, Sanchez JJ, Zhao Y, Feng J, Ling Y, Liu Y, Yu L, Rosell R, Liu B (2008) ERCC1 mRNA levels and survival of advanced gastric cancer patients treated with a modified FOLFOX regimen. Brit J Cancer 98(8):1398–1402. doi:10.1038/sj.bjc.6604317 PubMedCrossRef Wei J, Zou Z, Qian X, Ding Y, Xie L, Sanchez JJ, Zhao Y, Feng J, Ling Y, Liu Y, Yu L, Rosell R, Liu B (2008) ERCC1 mRNA levels and survival of advanced gastric cancer patients treated with a modified FOLFOX regimen. Brit J Cancer 98(8):1398–1402. doi:10.​1038/​sj.​bjc.​6604317 PubMedCrossRef
13.
Zurück zum Zitat Yeh CN, Jung SM, Chen TW, Hwang TL, Jan YY, Chen MF (2010) Expression of thymidylate synthase determines the response of gastric cancer patients undergoing gastrectomy to 5-fluorouracil-based adjuvant chemotherapy. Langenbecks Arch Surg 395(3):217–225. doi:10.1007/s00423-009-0573-x PubMedCrossRef Yeh CN, Jung SM, Chen TW, Hwang TL, Jan YY, Chen MF (2010) Expression of thymidylate synthase determines the response of gastric cancer patients undergoing gastrectomy to 5-fluorouracil-based adjuvant chemotherapy. Langenbecks Arch Surg 395(3):217–225. doi:10.​1007/​s00423-009-0573-x PubMedCrossRef
14.
Zurück zum Zitat Fukuda H, Takiguchi N, Koda K, Oda K, Seike K, Miyazaki M (2006) Thymidylate synthase and dihydropyrimidine dehydrogenase are related to histological effects of 5-fluorouracil and cisplatin neoadjuvant chemotherapy for primary gastric cancer patients. Cancer Invest 24(3):235–241. doi:10.1080/07357900600632082 PubMedCrossRef Fukuda H, Takiguchi N, Koda K, Oda K, Seike K, Miyazaki M (2006) Thymidylate synthase and dihydropyrimidine dehydrogenase are related to histological effects of 5-fluorouracil and cisplatin neoadjuvant chemotherapy for primary gastric cancer patients. Cancer Invest 24(3):235–241. doi:10.​1080/​0735790060063208​2 PubMedCrossRef
15.
Zurück zum Zitat Kwon HC, Roh MS, Oh SY, Kim SH, Kim MC, Kim JS, Kim HJ (2007) Prognostic value of expression of ERCC1, thymidylate synthase, and glutathione S-transferase P1 for 5-fluorouracil/oxaliplatin chemotherapy in advanced gastric cancer. Ann Oncol 18(3):504–509. doi:10.1093/annonc/mdl430 PubMedCrossRef Kwon HC, Roh MS, Oh SY, Kim SH, Kim MC, Kim JS, Kim HJ (2007) Prognostic value of expression of ERCC1, thymidylate synthase, and glutathione S-transferase P1 for 5-fluorouracil/oxaliplatin chemotherapy in advanced gastric cancer. Ann Oncol 18(3):504–509. doi:10.​1093/​annonc/​mdl430 PubMedCrossRef
16.
Zurück zum Zitat Yun J, Kim KM, Kim ST, Kim JH, Kim JA, Kong JH, Lee SH, Won YW, Sun JM, Lee J, Park SH, Park JO, Park YS, Lim HY, Kang WK (2010) Predictive value of the ERCC1 expression for treatment response and survival in advanced gastric cancer patients receiving cisplatin-based first-line chemotherapy. Cancer Res Treat 42(2):101–106. doi:10.4143/crt.2010.42.2.101 PubMedCrossRef Yun J, Kim KM, Kim ST, Kim JH, Kim JA, Kong JH, Lee SH, Won YW, Sun JM, Lee J, Park SH, Park JO, Park YS, Lim HY, Kang WK (2010) Predictive value of the ERCC1 expression for treatment response and survival in advanced gastric cancer patients receiving cisplatin-based first-line chemotherapy. Cancer Res Treat 42(2):101–106. doi:10.​4143/​crt.​2010.​42.​2.​101 PubMedCrossRef
17.
Zurück zum Zitat Klein D (2002) Quantification using real-time PCR technology: applications and limitations. Trends Mol Med 8(6):257–260PubMedCrossRef Klein D (2002) Quantification using real-time PCR technology: applications and limitations. Trends Mol Med 8(6):257–260PubMedCrossRef
18.
Zurück zum Zitat Matsubara J, Nishina T, Yamada Y, Moriwaki T, Shimoda T, Kajiwara T, Nakajima TE, Kato K, Hamaguchi T, Shimada Y, Okayama Y, Oka T, Shirao K (2008) Impacts of excision repair cross-complementing gene 1 (ERCC1), dihydropyrimidine dehydrogenase, and epidermal growth factor receptor on the outcomes of patients with advanced gastric cancer. Br J Cancer 98(4):832–839. doi:10.1038/sj.bjc.6604211 PubMedCrossRef Matsubara J, Nishina T, Yamada Y, Moriwaki T, Shimoda T, Kajiwara T, Nakajima TE, Kato K, Hamaguchi T, Shimada Y, Okayama Y, Oka T, Shirao K (2008) Impacts of excision repair cross-complementing gene 1 (ERCC1), dihydropyrimidine dehydrogenase, and epidermal growth factor receptor on the outcomes of patients with advanced gastric cancer. Br J Cancer 98(4):832–839. doi:10.​1038/​sj.​bjc.​6604211 PubMedCrossRef
19.
Zurück zum Zitat Zhang C, Li G, Fan C, Xu J, Cao J, Liu S, Li N (2012) Comparison of efficacy of different route of administration of chemotherapy on unresectable, advanced gastric cancer. World J Surg Oncol 10(1):162. doi:10.1186/1477-7819-10-162 PubMedCrossRef Zhang C, Li G, Fan C, Xu J, Cao J, Liu S, Li N (2012) Comparison of efficacy of different route of administration of chemotherapy on unresectable, advanced gastric cancer. World J Surg Oncol 10(1):162. doi:10.​1186/​1477-7819-10-162 PubMedCrossRef
20.
Zurück zum Zitat Sonnenblick A, Rottenberg Y, Kadouri L, Wygoda M, Rivkind A, Vainer GW, Peretz T, Hubert A (2012) Long-term outcome of continuous 5-fluorouracil/cisplatin-based chemotherapy followed by chemoradiation in patients with resected gastric cancer. Med Oncol 29(5):3035–3038. doi:10.1007/s12032-012-0302-0 PubMedCrossRef Sonnenblick A, Rottenberg Y, Kadouri L, Wygoda M, Rivkind A, Vainer GW, Peretz T, Hubert A (2012) Long-term outcome of continuous 5-fluorouracil/cisplatin-based chemotherapy followed by chemoradiation in patients with resected gastric cancer. Med Oncol 29(5):3035–3038. doi:10.​1007/​s12032-012-0302-0 PubMedCrossRef
21.
Zurück zum Zitat Johnston PG, Lenz HJ, Leichman CG, Danenberg KD, Allegra CJ, Danenberg PV, Leichman L (1995) Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res 55(7):1407–1412PubMed Johnston PG, Lenz HJ, Leichman CG, Danenberg KD, Allegra CJ, Danenberg PV, Leichman L (1995) Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res 55(7):1407–1412PubMed
22.
Zurück zum Zitat Becker K, Mueller JD, Schulmacher C, Ott K, Fink U, Busch R, Bottcher K, Siewert JR, Hofler H (2003) Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer 98(7):1521–1530. doi:10.1002/cncr.11660 PubMedCrossRef Becker K, Mueller JD, Schulmacher C, Ott K, Fink U, Busch R, Bottcher K, Siewert JR, Hofler H (2003) Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer 98(7):1521–1530. doi:10.​1002/​cncr.​11660 PubMedCrossRef
23.
Zurück zum Zitat Becker K, Langer R, Reim D, Novotny A, Meyer zum Buschenfelde C, Engel J, Friess H, Hofler H (2011) Significance of histopathological tumor regression after neoadjuvant chemotherapy in gastric adenocarcinomas: a summary of 480 cases. Ann Surg 253(5):934–939. doi:10.1097/SLA PubMedCrossRef Becker K, Langer R, Reim D, Novotny A, Meyer zum Buschenfelde C, Engel J, Friess H, Hofler H (2011) Significance of histopathological tumor regression after neoadjuvant chemotherapy in gastric adenocarcinomas: a summary of 480 cases. Ann Surg 253(5):934–939. doi:10.​1097/​SLA PubMedCrossRef
Metadaten
Titel
Correlation between expressions of ERCC1/TS mRNA and effects of gastric cancer to chemotherapy in the short term
verfasst von
Liqi Chen
Guoli Li
Jieshou Li
Chaogang Fan
Jian Xu
Bo Wu
Kun Liu
Caihua Zhang
Publikationsdatum
01.04.2013
Verlag
Springer-Verlag
Erschienen in
Cancer Chemotherapy and Pharmacology / Ausgabe 4/2013
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-013-2083-3

Weitere Artikel der Ausgabe 4/2013

Cancer Chemotherapy and Pharmacology 4/2013 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.